Fineotex Chemical Ltd (FCL)

Chemicals · Chemicals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹48.87 ↑ 103.79% (1Y)

🎯 Key Takeaways

Fineotex Chemical Ltd is in a high-growth phase driven by strategic acquisitions and global expansion, evidenced by 164% YoY revenue growth in Q1 FY27 and a 92% PAT increase, supported by strong margin expansion and ROCE above 25%. The company has successfully integrated CrudeChem Technologies and is scaling U.
Revenue grew 20% QoQ to ₹377 in Q1FY27.
⚠️ Integration risk from CrudeChem Technologies remains, as full synergies may take time to materialize.

Market Cap

₹5,691

P/E Ratio

14.7

P/B Ratio

7.78

ROE

20.3%

ROCE

25.6%

Debt/Equity

0.00

Div Yield

0.10%

Promoter

62.3%

✨ Ask AI About FCL 📊 Interactive Charts

📖 The Story

Fineotex Chemical Ltd is in a high-growth phase driven by strategic acquisitions and global expansion, evidenced by 164% YoY revenue growth in Q1 FY27 and a 92% PAT increase, supported by strong margin expansion and ROCE above 25%. The company has successfully integrated CrudeChem Technologies and is scaling U.S. operations, positioning itself for sustained profitability and long-term value creation.

📰 What's Happening

In Q1 FY27, Fineotex reported consolidated revenue of ₹386.72 crores (+164.48% YoY) and PAT of ₹48.21 crores (+92.67% YoY), with EBITDA up 134.69% to ₹59.14 crores, reflecting robust operational performance and margin improvement. Management highlighted successful integration of CrudeChem Technologies and commissioning of U.S. capacity expansion as key growth enablers. An investor call audio recording was released post-results, and the company scheduled its Q1 FY27 earnings call for July 24, 2026, where leadership discussed strategic progress and future outlook.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	138	184	314	377
Operating Profit	28	32	39	55
OPM %	20.4%	17.1%	12.5%	14.5%
Net Profit	26	30	44	48
EPS	₹2.27	₹0.26	₹0.38	₹0.41

Revenue has shown a sharp upward trend, rising from ₹138 crores in September 2025 to ₹377 crores by June 2026, with operating profit margins improving from 17.1% to 14.5% despite scale, indicating operating leverage. Net profit grew from ₹30 crores in December 2025 to ₹48 crores in June 2026, while EPS increased from ₹0.26 to ₹0.41, reflecting strong earnings momentum. This trajectory aligns with management’s narrative of scaling through acquisitions and global expansion, driving both top-line growth and profitability.

🔮 Management Outlook & What's Next

Management expressed confidence in sustaining the current margin profile and creating long-term value through the integration of CrudeChem Technologies and global expansion, particularly in the U.S. market. They emphasized operational execution and cost management as drivers of profitability, with no mention of near-term headwinds. The tone was constructive, focusing on scalable growth and capital efficiency, though no formal forward guidance was provided beyond the demonstrated execution in Q1 FY27.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	23	23	23	116
Reserves	666	708	756	766
Borrowings	0	0	0	8
Total Liabilities	766	815	878	1,159
Fixed Assets	172	179	192	203
Investments	286	330	348	317
Total Assets	766	815	878	1,159

The balance sheet shows a strong equity base of ₹116 crores with reserves of ₹766 crores as of March 2026, up from ₹23 crores equity in prior periods, indicating significant capital accumulation. Borrowings remain minimal at ₹8 crores, suggesting a conservative capital structure. Total assets have grown from ₹815 crores in March 2025 to ₹1,159 crores in March 2026, reflecting asset buildup likely tied to expansion. This supports a strategy of funding growth through retained earnings rather than debt, with room for strategic capital allocation.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+69
Investing	-273
Financing	+176
Net Cash Flow	-27

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	62.6%	62.3%	62.3%
FII	2.5%	2.9%	3.2%
DII	1.3%	1.3%	1.4%
Public	30.0%	29.8%	29.5%
# Shareholders	1,64,466	1,62,276	1,80,711

Promoter holding remains stable at 62.3% over the last three quarters, indicating confidence. FII and DII ownership have slightly declined from 2.52% and 1.28% in Q3FY26 to 3.16% and 1.35% in Q1FY27, respectively, though still modest. The number of public shareholders has increased to 1,80,711 from 1,62,276, suggesting broader retail interest. No significant dilution or selling by promoters or institutions has been observed, and the stable promoter stake supports continuity in strategic direction.

⚖️ Peer Comparison — Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
PIDILITIND	1.67 L Cr	63.2	33.4%	24.7%	0.01
SRF	76,535	35.4	15.6%	15.4%	0.36
LINDEINDIA	54,418	99.6	17.5%	12.8%	0.00
FLUOROCHEM	52,063	85.1	9.6%	7.7%	0.34
NAVINFLUOR	44,292	56.0	22.2%	19.9%	0.31
GODREJIND	38,842	33.0	9.2%	19.8%	4.57
HSCL	34,339	42.7	20.7%	17.1%	0.16
DEEPAKNTR	24,328	31.1	15.3%	13.4%	0.26
AETHER	22,349	94.8	13.8%	10.6%	0.08
AARTIIND	19,030	35.8	9.2%	9.5%	0.68

🔗 Peer Stock Analyses

PIDILITIND SRF LINDEINDIA FLUOROCHEM NAVINFLUOR

⚠️ Risk Factors

1. Integration risk from CrudeChem Technologies remains, as full synergies may take time to materialize. 2. High working capital of 72 days may pressure near-term liquidity despite strong cash flows. 3. Rising raw material costs could pressure margins if not fully passed on, though management currently expects blended margins to hold. 4. The proposed fundraise of up to ₹800 crores and related party transactions of ₹500 crores introduce execution and governance risks if not approved or utilized efficiently.

📋 Recent Filings

🧠 Analyst's Read

Fineotex Chemical is executing a clear growth strategy supported by strong financial performance and operational momentum, with management demonstrating consistent execution in integration and expansion. Investors should monitor the progress of U.S. capacity utilization, the outcome of the fundraise and AGM decisions, and the pace of margin sustainability. The company’s financial discipline and ROCE above 25% make it a compelling player in the specialty chemicals space, though capital allocation decisions will be critical in the next 6–12 months.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on FCL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FCL files new disclosures

Track FCL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FCL — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd